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Effect of Schiff base formation on the function of the calcitriol
receptor
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Effect of Schiff base formation on the function of the calcitriol receptor.
The genomic action of caleitriol is mediated through the interaction of the
calcitriol receptor (VDR) with vitamin D response elements (VDREs) of
the target genes. We have shown that the interaction of VDRs with
VDREs is inhibited by uremic toxins. We hypothesize that uremic toxins
form Schiff bases with the lysine residues of the VDR DNA binding
domain and inhibit the VDR interaction with the VDRE. In this study,
pyridoxal 5'-phosphate was used as a probe to test Schiff base formation
as the inhibitory mechanism, since it forms Schiff bases with steroid
receptors. Pyridoxal 5'-phosphate inhibited the VDR binding to the
VDREs and chemically modified the DNA binding domain of the VDR in
vitro. The inhibition was reversed when pyridoxal 5'-phosphate was
preincubated with lysine. Further, this chemical agent also blocked the
production of chioramphenicol acetyltransferase (CAT) enzyme induced
by calcitriol in cells transfected with a constructed VDRE attached to a
CAT reporter gene. This finding is consistent with the hypothesis that
pyridoxal 5-phosphate could interact with the VDR and impair its DNA
binding within cells. Since induction of 24-hydroxylase synthesis is a
receptor mediated process, we studied the effect of pyridoxal 5-phosphate
on the synthesis of renal 24-hydroxylase in rats. When pyridoxal 5'-
phosphate was infused to rats, renal 24-hydroxylase activity was sup-
pressed, consequently, degradation of calcitriol was also reduced in these
animals. Thus, chemicals capable of Schiff base formation potentially
could alter the physiological function of VDR and calcitriol.
The biological action of calcitriol is a receptor-mediated pro-
cess. The hormone-receptor complexes interact with vitamin D
response elements (VDREs) and thus regulate the transcription
of those genes. The interaction of VDRs with VDREs, however,
is inhibited by uremic toxins. Consequently, end-organ resistance
to calcitriol occurs in renal failure [1, 21. The mechanism of
inhibition by uremic toxins is unknown. However, since pyridoxal
5'-phosphate has been shown to form Schiff bases with steroid
receptors and inhibit the receptor's interaction with DNA [3—6],
we propose that compounds with reactive aldehydes or ketones in
uremic plasma block VDR-VDRE interactions by an analogous
Schiff base mechanism [7]. These chemical agents capable of
forming a Schiff base with the VDR could influence VDR
function and thereby alter calcitriol metabolism. Thus, we used
pyridoxal 5'-phosphate as a probe to test this hypothesis.
Methods
Electrophoretic mobility shift assay (EMSA) of recombinant or
intestinal VDR incubated with pyridoxal 5'-phosphate
JDR binding to the osteocalcin VDRE. Preparation of recombi-
nant human I'DR. Full length recombinant human VDR and
mouse retinoid X receptor a (RXRa) proteins were expressed
from the vector pMalc2 (New England Biolabs). This vector
produces a fusion protein of maltose binding protein followed by
a cleavage site for factor Xa and the recombinant protein. The
fusion proteins of VDR and RXRs are purified by affinity
chromatography on an amylose column and cleaved with factor
Xa as previously described [2].
Preparation of intestinal VDR. Rats were decapitated and the
initial 20 cm of small intestine distal to the pylorus (duodenum
and portion of jejunum) was removed and flushed with ice cold
Ca/Mg-free phosphate (6.6 msi Na2HPO4, 250 lU/mI Trasylol and
1.5 mrvt KH2PO4)-buffered saline (CMF-PBS). The mucosal cells
were scraped from the serosa, washed three times in 20 volumes
of CMF-PBS and centrifuged at 200 x g for five minutes after
each washing. The tissue was homogenized in a Polytron in 20 vol
(wt/vol) of buffer consisting of 300 mM KCI, 200 j.rg/ml soybean
trypsin inhibitor, 10 mvt Tris-HC1 (pH 7.4), 1 mi EDTA, 10 mM
sodium molybdate and 5 mrvi dithiothreitol (KTED) [8]. Cellular
protein was prepared by centrifugation at 100,000 X g for 45
minutes at 0 to 4°C.
Electrophoretic mobility shift assay (EMSA). A 36 base pair
synthetic oligonucleotide encompassing the rat osteocalcin gene
VDRE (base pairs —459 to —432 with CTAG overhangs [91) was
labeled by a fill-in reaction using the Klenow fragment of DNA
polymerase I and [a-32P]dCTP. The labeled DNA probe was
purified on a Sephadex G-50 column.
Approximately 250 ng of recombinant VDR and 100 ng of
RXRa were incubated for one hour with various concentrations
of pyridoxal 5'-phosphate (0.5, 1.0, 2.5 and 5 mM). Thereafter, the
proteins were incubated for another 15 minutes in 35 l of
mobility shift reaction buffer containing 5 ms'i Tris, IS mM Hepes,
3.5 mM MgCI2, 5 msi EDTA, 10% glycerol, 0.1% Tween 20, 5 mM
dithiothreitol, 0.15 .tg poly(dl-dC), and 100 mat KCI, pH 7.9 [2].
At the end of this incubation, approximately 30,000 cpm of
radiolabeled osteocalcin VDRE probe was added in each mobility
shift reaction mixture. The reaction mixtures were gently vor-
tcxcd, incubated for another 10 minutes and electrophoresed on
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6% nondenaturing polyacrylamide gels at 100 V for approxi-
mately three hours. The mobility shift running buffer contained 50
mM Tris, 380 msi glycine, and 2 mst EDTA (pH 8.5) [21. The gels
were dried and autoradiographed.
Schiff base reaction of pyridoxal 5'-phosphate and lysine. To test
if pre-formation of a Schiff base between pyridoxal 5'-phosphate
and lysine may reverse the inhibitory effect of pyridoxal 5'-
phosphate on VDR binding to osteocalcin VDRE, we incubated
5 mM pyridoxal 5'-phosphate with 20 mrvt 1-lysine (pH 7.4) at 37°C
for 12 days [101. During the preincubation, the aldehyde group of
the pyridoxal 5'-phosphate is presumably in Schiff base linkage
with the €-amino group of free lysine. The mixtures were then
incubated with intestinal cellular proteins (approximately 40 jg
cellular protein) for electrophoretic mobility shift assay as above.
JDR binding to osteopontin
Preparation of a truncated VDR. We produced a truncated VDR
(amino acids ito 119) that lacked the ligand binding domain. The
PCR-based splicing by overlap extension technique was used to
place a stop codon after amino acid 119 with a standard protocol
and expressed in an E. coli expression plasmid vector pMalc2
(New England Biolabs). This vector produces a fusion protein of
maltose binding protein followed by a cleavage site for factor Xa
and the recombinant truncated VDR. The fusion proteins of
VDR were purified as above. The truncated VDR includes the
full zinc fingers, T and A box domains, but lacks the ligand binding
domain.
A 32 bp synthetic oligonucleotide encompassing the rat os-
teopontin gene VDRE (bp —761 to —738 plus GATC overhangs
[11]) was labeled by a fill-in reaction and used as a probe. EMSA
incubations utilized approximately 10 jig of the truncated VDR.
Receptors were incubated individually for one hour at 15°C with
0 or 5 mM pyridoxal 5'-phosphate. Thereafter, these receptor
preparations were added to EMSA incubations as described
above.
Effect of pyridoxal 5'-phosphate on calcitriol-dependent expression
of a reporter gene in transfected JEG-3 cells
We used transiently transfected JEG-3 cells to study the effect
of pyridoxal 5'-phosphate on VDR binding to VDRE [21. JEG-3
cells are derived from human choriocarcinoma cells which do not
contain VDR or VDRE. The human VDR eDNA was expressed
from the vector pCDM. The VDR eDNA was expressed from a
cytomegalovirus promoter that itself is not calcitriol responsive.
The reporter plasmid was derived from pUTKAT3 [11], and
contained two copies of the sequence 5'-GATCCACTAGGT-
CAAGGAGGTCATGGATC ligated 5' to the basal thymidine
kinase promoter driving expression of chloramphenicol acetyl-
transferase (CAT) (pTKD2AA). An internal control plasmid
expressing human growth hormone (GH) from the basal thymi-
dine kinase promoter (pTKGH) was utilized to control for
transfection efficiency. Transfections included 4 jig of pTKD2AA,
10 ng of pCDMVDR, I jig of pTKGH, and 6 jig of pCDM as filler
plasmid per 60 mm Petri dish. Cells were cultured 100 flM
calcitriol for 24 hours following transfection. Pyridoxal 5'-phos-
phate was added for 24 hours following transfection at a final
concentration of 0.5 m. Cell lysates were analyzed for CAT
activity and media for human GH as described [121. Fold CAT
induction is defined as CAT/human GH for cells cultured with
Infusion rate of 3H-calcitriol
Analytical methods
calcitriol divided by CAT/human GH for cells cultured without
calcitriol.
Metabolic clearance rate (MCR) of calcitriol in normal rats
infused with pyridoxal phosphate
Normal Sprague-Dawley rats (200 to 230 g) fed with regular
Purina rat chow containing 1.0% Ca, 0.8% P, and 4.5 IU per g
vitamin D were used throughout the study. On the day of
experimentation, rats were weighed and anesthetized with ether.
The femoral artery and vein were cannulated with polyethylene
tubing (PE) for blood sampling and fluid infusion. A PE 50 tube
was inserted into the bladder for urine collection. The animals
were placed in individual cages and allowed to awaken before the
experiment.
Animals (N = 6) were infused through femoral vein for 20
hours with 20 ml normal saline solution containing 4 mg/100 g
body wt pyridoxal phosphate and 0.05 jiCi of radiolabeled calcit-
riol (la,25 [26, 27(n)-3H] dihydroxyvitamin D3, 160 Ci/mmol. New
England Nuclear). The metabolic clearance of calcitriol detailed
in a previous communication [13] was determined 18 and 20 hours
after the infusion. Control animals (N = 6) were infused with 20
ml normal saline containing radiolabeled calcitriol.
Arterial blood samples (0.5 ml) were drawn 18 and 20 hours
after the fluid infusion and the plasma concentrations of radioac-
tive calcitriol were determined [131. The intraassay and interassay
coefficients of variation for radioactive calcitriol were 6.8% and
6.7%. Since there was no difference in the calculated MCR at 18
and 20 hours, only the average values of the MCR were presented
in this study.
At the end of infusion, arterial blood was obtained for the
measurement of calcitriol, calcium, phosphorus, and creatinine.
Urine was collected during the 20-hour infusion for the measure-
ment of calcium, phosphorus, and creatinine. Animals were fasted
during the infusion.
The MCR of calcitriol was calculated as [131:
MCR =
Mean steady state plasma concentration of 3H-calcitriol
The production rate (PR) of calcitriol is calculated as:
PR = MCR >< endogenous plasma concentration of calcitriol
Calcium was measured with an atomic absorption spectropho-
tomcter (Model 306, Perkin Elmer, Norwalk, CT, USA). Phos-
phorus and creatinine were measured as described previously [14].
Plasma calcitriol was measured in duplicate according to the
methods of Reinhardt et al [15] and Hollis [161. Our interassay
coefficients of variation were 7.0% for low control (20 pg/mI, N =
12) and 4.1% for high control (100 pg/ml, N = 12). The intraassay
coefficients of variation were 5.4% for low control (N = 6) and
4.7% for high control (N = 6), respectively. Calcitriol recovery
averaged 65%.
Renal 24-hydroxylase activity in normal rats' infused with pyridoxal
phosphate
Normal rats were weighed and anesthetized with ether. The
veins were cannulated with polyethylene tubing (PE) for fluid
infusion. A PE 50 tube was inserted into the bladder for urine
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collection. The animals were placed in individual cages and
injected with a bolus of 250 nglkg calcitriol, followed by infusion
for 20 hours with 20 ml saline solution containing 4 mgIlOO g
pyridoxal phosphate (N = 6) or 20 ml of saline solution (N = 6).
At the end of infusion, animals were anesthetized with ether and
bloods were drawn from the aorta. The kidneys were perfused
with 10 ml of ice-cold homogenizing buffer solution and removed
for measurements of 24-hydroxylase activity.
Renal 24-hydroxylase activity was measured as previously de-
scribed [17, 18]. Kidneys were quickly homogenized in ice-cold
oxygenated buffer solution containing 10 mrvi Tris-acetate (pH
7.4), 2 m magnesium acetate, 0.19 M sucrose. A 5% weight to
volume homogenate was prepared in Tris-acetate buffer solution.
Two ml of the homogenate was placed in a 25 ml Erlenmeyer flask
and added with one ml of ice-cold oxygenated homogenization
buffer containing 25 m sodium succinate. The reaction was
initiated by the addition of 240 nmol cold 25(OH)D3 and 0.25 xCi
25-OH [26, 27(n)-3H]D3 (158 Ci!mmol, New England Nuclear).
The homogenates were incubated at 37°C for 30 and 60 minutes.
The reaction was stopped by the addition of 20 ml methanol-
chloroform (2:1 vol/vol). One xg of cold 24,25(OH)2D3 was added
to each flask to monitor the recovery of 3H-24,25(OH)2D3. The
samples were extracted by the method of Bligh and Dryer as
modified by Lobaugh and Drezner [19]. The chloroform extracts
were reconstituted in 0.5 ml absolute ethanol. Two hundred
microliters of each sample was further extracted on a C18 column
and dried under nitrogen. These samples were dissolved in 500 1.d
of HPLC solvent containing hexane-isopropanol-methanol (88:10:
2). The samples were injected into the HPLC and extracted on
two Zorbax-Sil columns (0.46 X 25 cm) placed in series at a flow
rate of 4 mI/mm. The peak containing 24,25(OH)2D3 and
25(OH)D3 was collected into tubes, dried and dissolved in HPLC
mobile phase containing hexane-isopropanol-methanol (96:3:1)
and chromatographed on a Zorbax-Sil column at a flow rate of 4
mi/mm to separate 24,25(OH)2D3 from 25(OH)D3 [18, 201. The
peak containing 24,25(OH)2D3 was collected into scintillation
vials for radioactivity measurements.
All data were expressed as mean SEM. Statistical analysis was
performed using Student's t-test. A P value of < 0.05 was
considered significant.
Results
Electrophoretic mobility shift assay (EMSA) of recombinant or
intestinal VDR incubated with pyridoxal 5'-phosphate
The effect of pyridoxal 5'-phosphate on the VDR-VDRE
interaction is depicted in Figure 1. The pyridoxal 5'-phosphate
inhibited the interaction of VDR with osteocalcin VDRE in a
dose related manner. However, pyridoxal 5'-phosphate preincu-
bated with lysine for 12 days no longer inhibited intestinal VDR
binding to osteocalcin VDRE (Fig. 2).
The truncated VDR (119 amino acids) also had decreased
binding affinity for osteopontin VDRE when it was pre-incuhated
with 5 mi pyridoxal 5'-phosphate for one hour (Fig. 3). This
indicates that pyridoxal 5'-phosphate interacts with the VDR
DNA binding domain, not the ligand binding domain.
Effect of pyridoxal 5'-phosphate on the calcitriol-dependent
expression of a reporter gene in transfected JEG-3 cells
JEG-3 cells were transiently transfccted with a VDR expression
piasmid, a VDRE-containing CAT reporter plasmid, and an
Fig. 1. Effect of pyridoxal 5-phosphate (B<,) on J/DR-VDRE complex
formation analyzed by EMSA. Lane 1, free radiolabeled osteocalcin
VDRE; lane 2, E. coli derived recombinant VDR plus RXR with VDRE;
lanes 3 to 6, VDR incubated with 0.5, 1.5, 3, 5 mrvi pyridoxal 5'-phosphate,
respectively, for one hour prior to the EMSA incubation.
internal control plasmid expressing human GH. In the absence of
transfected VDR, calcitriol did not induce CAT (average 0.99-
fold, N = 4). However, following cotransfection with the expres-
sion vector pCDMVDR, calcitriol induced CAT activity 8.3-fold
(Fig. 4, control). Addition of pyridoxal 5-phosphate inhibited
more than 20% of calcitriol-induced CAT activity (6.3-fold; Fig.
4). Furthermore, this effect of pyridoxal 5'-phosphate was on the
caleitriol-induced activity, not the basal CAT activity (control,
18.0 3.6 vs. pyridoxal 5'-phosphate, 11.2 5.6% conversion,
P = NS) or human GH expression (control, 0.63 0.19 vs.
pyridoxal 5'-phosphate, 0.41 0.26 ng/ml, P = NS).
Metabolic clearance of calcitriol in normal rats infused with
pyridoxal phosphate
Infusion of pyridoxal 5'-phosphate influenced neither calcium
and phosphate excretions nor their plasma concentrations (Table
1). However, pyridoxal 5'-phosphate significantly reduced the
B6
Dose mM
Lane
VDR+RXR — + + + + +
— + + + + +
o o 0.5 1.5 3 5
1 2 3 4 5 6
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metabolic clearance rate of calcitriol. Consequently, the plasma
concentration of calcitriol was increased because of decreased
calcitriol degradation. Production of calcitriol, however, was not
affected by pyridoxal 5'-phosphate (Table 2).
Renal 24-hydroxylase activity in normal rats infused with pyridoxal
5'-phosphate
Infusion of pyridoxal 5-phosphate significantly suppressed
24-hydroxylase activity (Fig. 5). Thus, decreased 24-hydroxylase
activity could account for the decreased metabolic clearance of
calcitriol, though pyridoxal 5'-phosphate could suppress other
degradation enzymes as well.
Discussion
The genomic action of calcitriol is mediated through the
interaction of calcitriol receptor (VDR) with vitamin D response
elements (VDREs) of the target genes. The hormone-receptor
complex interacts with specific DNA response elements, generally
located in the 5' flanking regions of target genes. This interaction
results in production of protein that carry out the biological
activity of calcitriol [21]. However, the biological activity of
calcitriol is decreased in renal failure [22, 231, and one of the
reasons is that uremic plasma contains factors that inhibit the
interaction of hormone-receptor complex with VDRE [2]. Fur-
ther, uremic toxins also alter the physiological action of calcitriol
VDR - + + + + + VDR - + +
Lys — — — — + + Pyridoxal-P04 (mM) — 0 5 mM
B6 — — + + + — Lane 1 2 3
Lane 1 2 3 4 5 6
Fig. 3. Inhibition of a truncated VDR (VDR DNA binding domain) binding
Fig. 2. Inhibito,y effect of pyridoxal 5-phosphate on VDR-RXR-VDRE to radiolabeled osteopontin VDRE by pyridoxal 5'-phosphate. Lane 1, free
complex is reversed by 1-lysine. Lane 1, free radiolabeled osteocalcin radiolabeled osteopontin VDRE; lane 2, truncated VDR-VDRE complex;
VDRE; lane 2, intestinal VDR-VDRE complex; lane 3, addition of 5 mM lane 3, truncated VDR preincubated with 5 mai pyridoxal 5'-phosphate for
pyridoxal 5'-phosphate abolished VDR-VDRE complex; lane 4, addition one hour could no longer bind to the VDRE.
of 5 mi pyridoxal 5'-phosphate preincubated in water at 37°C for 12 days
also abolished VDR-VDRE complex; lane 5, addition of 5 mM pyridoxal
5'-phosphate preincubated with 20 mrvt 1-lysine at 37°C for 12 days failed
to inhibit VDR binding to VDRE; lane 6, addition of 20 mrvi 1-lysine
preincuhated at 37°C for 12 days did not inhibit VDR-VDRE complex
formation.
Pc0 001
Control Pyridoxal 5-phosphate
C
>
C
>
+
C0
a
C
00
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Fig. 4. Effect of pyridoxal 5'-phosphate on calcitriol-induced expression of
CAT activity on transfected JEG-3 cells. JEG-3 cells were transfected with
a VDR expression vector, a CAT reporter plasmid driven by a calcitriol
responsive promoter, and a human GH-expressing reporter as an internal
control. Cells were incubated with 0 (control) and 2.5 m (experimental)
pyridoxal 5'-phosphate, in each case with or without 100 nM calcitriol, for
48 hours. Fold CAT induction is defined as CAT/human GH for cells
cultured without calcitriol. Results arc the mean SE for 5 independent
transfections.
within the cells, perhaps through inhibition of VDR interaction
with VDREs [21.
Although the chemical structures of the uremic toxins remain
unknown, we speculate that some of the chemicals have reactive
aldehyde or ketone groups that form Schiff bases with lysine
residues of the VDR DNA binding domain, thereby reducing
VDRs binding affinity for VDREs. This supposition is based on
the following reasons. (1) The DNA binding domain is sensitive to
chemical modification [24], and a point mutation in the gene
coding this domain impairs the VDR function [25, 26]. (2)
Pyridoxal 5'-phosphate has a reactive aldehyde group and is
capable of forming a Schiff base with steroid receptors and
reducing steroid receptor-DNA binding [3—6]. (3) Uremic plasma
contains chemical compounds with reactive aldehydes or ketones
[27].
In this study, we provide evidence to support the hypothesis
that Schiff base formation is responsible for the inhibitory mech-
anism of uremic toxins that impair VDR interaction with VDREs.
We have shown that pyridoxal 5'-phosphate inhibited VDR
binding to osteocalcin VDRE. We have also shown that pyridoxal
5'-phosphate inhibited the binding of a truncated VDR to the
osteopontin VDRE (and osteocalcin VDRE, unpublished obser-
vation). Since the truncated VDR contains the VDR DNA
binding domain and lacks the hormone binding domain, inhibition
of the binding suggests that the pyridoxal 5'-phosphate alters the
DNA binding domain of the VDR. Further, when pyridoxal
5'-phosphate was pre-incubated with lysine for 12 days, the
pyridoxal 5'-phosphate failed to inhibit VDR binding to osteocal-
cm VDRE. This is consistent with the expectation that by reacting
with free ly.sine, the pyridoxal 5'-phosphate aldehyde group would
no longer be available to form a Schiff base with lysine residues in
the VDR DNA binding domain.
If pyridoxal 5'-phosphate could chemically modify the VDR in
vitro, it might be possible to detect an effect of pyridoxal 5'-
phosphate on the biological action of calcitriol within cells. Thus,
we introduced a VDRE-CAT reporter gene to JEG-3 cells [2] and
used these transiently transfected cells to study the effect of
pyridoxal 5 '-phosphate on VDR activity. We found that pyridoxal
5'-phosphate inhibited the calcitriol induced CAT activity, sug-
gesting that pyridoxal 5'-phosphate can impair the VDR-VDRE
interaction within cells. Furthermore, we examined the effect of
pyridoxal 5'-phosphate on the in vivo activity of 24-hydroxylase, a
process that requires VDR interaction with a specific VDRE [28,
291. If pyridoxal 5'-phosphate inhibits this interaction in vivo, it
could reduce the synthesis of 24-hydroxylase. We found that
infusion of pyridoxal 5'-phosphate into rats indeed significantly
reduced renal 24-hydroxylase activity, suggesting that pyridoxal
5'-phosphate can chemically modify the VDR in vivo. The de-
creased activity of this calcitriol degradation enzyme activity
accounted for the decreased calcitriol metabolic clearance rate in
pyridoxal 5'-phosphate infused animals.
Steroid receptor superfamily members share structural homol-
ogy in their DNA binding domains. These receptors have three
major regions (Ito III) of conserved amino acids [211. Region I
includes the DNA binding domain and contains a sequence of 66
highly conserved amino acids. Region II and III are located within
the C-terminal or hormone binding domain of the receptor. The
DNA binding domain has two zinc fingers that contain eight
cysteine residues and two zinc molecules [30]. The cVDR DNA
binding domain has seven lysine residues, three of which are
highly conserved [31]. We predict that uremic toxins may also
inhibit other steroid receptors binding to DNAs, perhaps through
chemical modification of the receptor DNA binding domains.
In summary, we have demonstrated that pyridoxal 5'-phosphate
can inhibit VDR-VDRE interaction in vitro. Pyridoxal 5'-phos-
phate also blocked calcitriol induced expression of CAT activity in
transiently transfected JEG cells. When pyridoxal 5'-phosphate
was infused into rats, the synthesis of 24-hydroxylase, a receptor
mediated product, was reduced. Taken together, the data indi-
cated that pyridoxal 5'-phosphate can inhibit VDR binding to
VDRE, presumably through formation of Schiff base with lysine
residues of the VDR DNA binding domain. Hence pyridoxal
5'-phosphate and uremic toxins could share similar properties in
the regulation of the VDR and 24-hydroxylase activity. Although
these substances remain unidentified (and probably are distinct
from pyridoxal 5'-phosphate), they are likely to contain reactive
aldehydes or ketones [27]. This group of compounds potentially
could be responsible for abnormal calcitriol metabolism in renal
failure by a mechanism similar to that demonstrated here for the
model compound pyridoxal 5'-phosphate.
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Table 2. Metabolic production and clearance of calcitriol in rats
infused with pyridoxal 5'-phosphate
Groups
Plasma calcitriol
pg/mt
MCR
pJ/min/100 g
PR
ng/kg/day
Control 65.7 3.26 26.7 0.94 25.2 1.16
Pyridoxal 5'-phosphate 87.9 2.25 19.7 0.64 25.0 1.24
P values <0.001 <0.001 NS
Abbreviations are: MCR, metabolic clearance rate; PR, production
rate.
Fig. 5. Renal 24-hydroxylase activity of rats infused with normal saline or 4
mgIlOO g pyridoxal 5-phosphate.
provided by Dr. H. DeLuca. We wish to thank Yin Xu for her technical
assistance.
Reprint requests to Chen H. Hsu, M.D., 3914 Taubman Center, Nephrol-
o,ey Division, University Hospital, Ann Arbor, Michigan 48109-0364, USA.
References
1. PATEL S, KE ITQ, VANIIOLDER R, Hsu CH: Inhibition of nuclear
uptake of calcitriol receptor by uremic ultrafiltrate. Kidney lot 46:129—
133, 1994
2. PATEL SR, Ka 11-Q, VAN! IOLDER R, KOENIG RJ, Ilsu CH: Inhibition
of calcitriol receptor binding to vitamin D response elements by
uremic toxins. J Clin Invest 96:50—59, 1995
3. MULLER RE, TRAISH A, WoTIz HH: Effects of pyridoxal 5-phosphate
on uterine estrogen receptor. I. Inhibition of nuclear binding in
cell-free system and intact uterus. J Biol Chem 255:4062—4067, 1980
4. NsHiGom H, ToFr D: Chemical modification of the avian progester-
one receptor by pyridoxal 5'-phosphate. J Bio! Chem 254:9155—9161,
1979
5. Disouo DM, PHELPS DS, OHL VS, LITWACK G: Pyridoxine deficiency
influences the behavior of the glucocorticoid receptor complex. J Bio!
Chem 255:3866—3870, 1980
6. CAKE MH, DISORBO DM, LITWACK G: Effect of pyridoxal phosphate
on the DNA binding site of activated hepatic glucocorticoid receptor.
J Biol Chem 253:4886—4891, 1978
7. Hsu CH, PATEL SR, YOUNG EW, VANHOLDER R: The biological
action of caleitriol in renal failure. Kidney mt 46:605—612, 1994
8. HIRST M, FELDMAN D: Cleavage of the rat intestinal 1.25-dihydroxyvi-
tamin D3 receptor by an endogenous protease to a form with defective
DNA binding. Arch Biochem Biophys 250:153—161, 1986
9. DEMAY MB, KIERNAN MS, DELUCA HF, KRONENBERG HM: Charac-
terization of 1,25-dihydroxyvitamin D1 receptor interactions with
target sequences in the rat osteocalcin gene. Mo! Endocrinol 6:557—
562, 1992
10. HIGGINS PJ, BUNN HF: Kinetic analysis of the nonenzymatic glycosy-
lation of hemoglobin. J Biol Chem 256:5204—5208, 1981
11. NODA M, VOGEL RL, CRAIG AM, PRAHL J, DELUCA HF, DENHARDT
DT: Identification of a DNA sequence responsible for binding of the
1.25-dihydroxyvitamin D3 receptor and 1.25-dihydroxyvitamin D3 en-
hancement of mouse secreted phosphoprotein 1 (Spp-1 or osteopon-
tin) gene expression. Proc Nat! Acad Sci USA 87:9995—9999, 1990
12. ROSEN ED, BENINGHOF EG, KOENIG RJ: Dimerization interfaces of
thyroid hormone, retinoic acid, vitamin D and retinoid X receptors.
JBiot Chem 268:11534—11541, 1993
13. HSU CH, PATEL SR, YOUNG EW, SIMPSON RU: Production and
degradation of calcitriol in renal failure rats. Am J Physiol 253:F1015—
F1019, 1987
14. HSU CH, PATEL S: Factors influencing calcitriol metabolism in renal
failure. Kidney mt 37:44—50, 1990
15. REINHARDT TA, HORST RL, ORF JW, HOLLIS BW: A microassay for
1,25-dihydroxyvitamin D not requiring high performance liquid chro-
matography: Application to clinical studies. J Clin Endocrinol Metab
58:91—98, 1984
16. HoluS BW: Assay ofcirculating 1,25-dihydroxyvitamin D involving a
novel single-cartridge extraction and purification procedure. C!in
hem 32:2060—2063, 1986
17. ITORIUCHIN,SIIINKI T, SUDA S, TAKAHASHI N, YAMADA S, TAKAYAMA
H, SUDA T: A rapid and sensitive in vitro assay of 25-hydroxyvitamin
Dr1 alpha-hydroxylase and 24-hydroxylase using rat kidney homoge-
nates. Biochem Biophys Res Commun 121:174—180, 1984
18. HALLORAN BP, BIKLE DD, LEVENS MJ, CASTRO ME, GLOBUS RK,
HOLTON F.: Chronic 1,25-dihydroxyvitamin D3 administration in the
rat reduces the serum concentration of 25-hydroxyvitamin D by
increasing metabolic clearance rate. J Clin Invest 78:622—628, 1986
19. LOBAIJGH B, DREZNER MK: Measurement of 25-hydroxyvitamin
D-la-hydroxylase activity in mammalian kidney. Anal Biochem 129:
416—424, 1983
20. NAPOLI JL, KOSZEWSKI NJ, HORST RL: Vitamins and eoenzymes (Part
H), in isolation and identification of vitamin D metabolites, Methods
Table 1. Plasma concentrations of creatinine, calcium and phosphate, and urinary excretion of calcium and phosphate in rats infused with
pyridoxal 5'-phosphate
Body weight
Groups g
C.
m!/min/100 g
Pea
mg/dl
Pp
mg/dl
UcaV
pg/mm
UV
pg/mm
Control 212 4.9 0.52 0.02 9.80 0.10 7.94 0.14 0.18 0.03 19.7 2.68
Pyridoxal 5-phosphate 210 2.2 0.54 0.03 9.83 0.21 7.88 0.14 0.21 0.03 20.1 1.59
P values NS NS NS NS NS NS
Abbreviations are: Ccr, creatinine clearance; Pea, plasma calcium; Pp, plasma phosphorus; urinary calcium excretion; UV, urinary phosphate
excretion; NS, not significant.
Patel et a!: Pyridoxal 5'-phosphate and calcitriol receptor 1545
in Enzymology, edited by MCCORMICK FCADB, New York, Academic
Press, Inc. Harcourt Brace Jovanovich, 1986
21. MCMALLEY B: The steroid receptor superfamily: More excitement
predicted for the future. Mo! Endocrinol 4:363—369, 1990
22. WALLING MW, KIMBERG DV, WASSERMAN RH, FEINBERG RR:
Duodenal active transport of calcium and phosphate in vitamin
D-deflcient rats: Effects of nephrectomy. Cestrum diurnum, and
lalpha,25-dihydroxyvitamin D3. Endocrino!ogy 98:1130—1134, 1976
23. FUKAGAWA M, KANAME S, IGARASHI T, OGATA E, KUROKAWA K:
Regulation of parathyroid hormone synthesis in chronic renal failure
in rats. Kidney mt 39:874—881, 1991
24. PIKE JW: Evidence for a reactive sulfbydryl in the DNA binding
domain of the 1,25-dihydroxyvitamin D3 receptor. Biochem Biophys
Res Commun 100:1713—1719, 1981
25. SONE T, SCOTT RA, HUGHES MR, MALLOY PJ, FELDMAN D,
O'MALLEY BW, PIKE JW: Mutant vitamin D receptors which confer
hereditary resistance to 1,25-dihydroxyvitamin D3 in humans are
transcriptionally inactive in vitro. J Bio! Chem 264:20230—20234, 1989
26. MALLOY PJ, HOCIIBERG Z, TIOSANO D, PIKE JW, HUGHES MR,
FELDMAN D: The molecular basis of hereditary 1,25-dihydroxyvitamin
D3 resistant rickets in seven related families. J Gun Invest 86:2071—
2079, 1990
27. PAPANASTASIOU P, GRASS L, RODELA H, PATRIKAREA A, OREoPouws
D, DIAMANDIS EP: Immunological quantification of advanced glyco-
sylation end-products in the serum of patients on hemodialysis or
CAPD. Kidney mt 46:216—222, 1994
28. COLSTON KW, EVANS TM, SPELSBERG TC, MACINTYRE I: Feedback
regulation of vitamin D metabolism by 1,25-dihydroxycholecalciferol.
Biochem J 164:83—89, 1977
29. Col.sToN K, FELDMAN D: Nuclear translocation of the 1,25-dihydroxy-
cholecalciferol receptor in mouse kidney. J Biol Chem 255:7510—7513,
1980
30. LUIsI BF, Xu WX, OTWINOWSKI Z, FREEDMAN LP, YAMAMOTO KR,
SIGLER PB: Crystallographic analysis of the interaction of the glu-
cocorticoid receptor with DNA. Nature 352:497—505, 1991
31. EVANS RM: The steroid and thyroid hormone receptor superfamily.
Science 240:889—895, 1988
